Regeneron Pharmaceuticals

2014 was the year Regeneron’s Genetics Centre became fully operational, and new research collaborations, including with Columbia University, were announced. The centre will allow Regeneron to continue its work in biopharmaceuticals

New York-based biotech giant Regeneron has been much lauded for its research and development department and forward-looking strategies. The company has won a long list of awards in the biotech sphere, and has been widely recognised as an outstanding place to work. Regeneron’s long list of product successes includes EYLEA, which was developed to help treat a cause of blindness among the elderly population. The firm continues to grow in a variety of directions, lending its expertise to a variety of causes.